387 related articles for article (PubMed ID: 26229480)
1. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
Detournay B; Halimi S; Robert J; Deschaseaux C; Dejager S
Vasc Health Risk Manag; 2015; 11():417-25. PubMed ID: 26229480
[TBL] [Abstract][Full Text] [Related]
2. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Göke R; Gruenberger JB; Bader G; Dworak M
Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
[TBL] [Abstract][Full Text] [Related]
3. Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues.
Gautier JF; Monguillon P; Verier-Mine O; Valensi P; Fiquet B; Dejager S; Charbonnel B
Diabetes Res Clin Pract; 2016 Jun; 116():26-8. PubMed ID: 27321312
[TBL] [Abstract][Full Text] [Related]
4. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
[TBL] [Abstract][Full Text] [Related]
5. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
Liu X; Men P; Wang Y; Zhai S; Liu G
Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
[TBL] [Abstract][Full Text] [Related]
6. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
[TBL] [Abstract][Full Text] [Related]
8. Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model.
Omar BA; Vikman J; Winzell MS; Voss U; Ekblad E; Foley JE; Ahrén B
Diabetologia; 2013 Aug; 56(8):1752-60. PubMed ID: 23636640
[TBL] [Abstract][Full Text] [Related]
9. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus.
Fonseca V; Baron M; Shao Q; Dejager S
Horm Metab Res; 2008 Jun; 40(6):427-30. PubMed ID: 18401832
[No Abstract] [Full Text] [Related]
10. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
Chang CH; Chang YC; Lin JW; Caffrey JL; Wu LC; Lai MS; Chuang LM
Int J Cardiol; 2016 Oct; 220():14-20. PubMed ID: 27389437
[TBL] [Abstract][Full Text] [Related]
11. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Azuma K; Rádiková Z; Mancino J; Toledo FG; Thomas E; Kangani C; Dalla Man C; Cobelli C; Holst JJ; Deacon CF; He Y; Ligueros-Saylan M; Serra D; Foley JE; Kelley DE
J Clin Endocrinol Metab; 2008 Feb; 93(2):459-64. PubMed ID: 18042650
[TBL] [Abstract][Full Text] [Related]
12. Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin.
de Ranitz-Greven WL; Beulens JW; Hoeks LB; Belle-van Meerkerk G; Biesma DH; de Valk HW
BMC Res Notes; 2014 Aug; 7():579. PubMed ID: 25175981
[TBL] [Abstract][Full Text] [Related]
13. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
14. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
Halimi S; Raccah D; Schweizer A; Dejager S
Curr Med Res Opin; 2010 Jul; 26(7):1647-56. PubMed ID: 20441397
[TBL] [Abstract][Full Text] [Related]
15. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.
Flock G; Baggio LL; Longuet C; Drucker DJ
Diabetes; 2007 Dec; 56(12):3006-13. PubMed ID: 17717280
[TBL] [Abstract][Full Text] [Related]
16. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.
Schweizer A; Dejager S; Foley JE; Kothny W
Vasc Health Risk Manag; 2011; 7():49-57. PubMed ID: 21415917
[TBL] [Abstract][Full Text] [Related]
17. New treatments for type 2 diabetes--the DPP4 inhibitors.
Gadsby R
Prim Care Diabetes; 2007 Dec; 1(4):209-11. PubMed ID: 18632049
[TBL] [Abstract][Full Text] [Related]
18. [Vildagliptin].
Iwamoto Y
Nihon Rinsho; 2011 May; 69(5):865-70. PubMed ID: 21595273
[No Abstract] [Full Text] [Related]
19. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
20. The role of vildagliptin in the management of type 2 diabetes mellitus.
Kleppinger EL; Helms K
Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
